Search hospitals > New Mexico > Albuquerque
Presbyterian Kaseman Hospital
Claim this profileAlbuquerque, New Mexico 87110
Global Leader in Breast Cancer
Global Leader in Parotid Gland Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
80 reported clinical trials
12 medical researchers
Summary
Presbyterian Kaseman Hospital is a medical facility located in Albuquerque, New Mexico. This center is recognized for care of Breast Cancer, Parotid Gland Cancer, Breast cancer, Non-Small Cell Lung Cancer, Lung Cancer and other specialties. Presbyterian Kaseman Hospital is involved with conducting 80 clinical trials across 220 conditions. There are 12 research doctors associated with this hospital, such as Atul Kumar, Carolyn Y. Muller, Ursa A. Brown-Glaberman, and Neda Hashemi Sadraei.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
2Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Atul KumarUniversity of New Mexico Cancer Center5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
22 reported clinical trials
38 drugs studied
Carolyn Y. MullerUniversity of New Mexico Cancer Center1 year of reported clinical research
Studies Endometrial Cancer
Studies Parotid Gland Cancer
23 reported clinical trials
44 drugs studied
Ursa A. Brown-GlabermanUniversity of New Mexico Cancer Center5 years of reported clinical research
Studies Breast Cancer
Studies Parotid Gland Cancer
20 reported clinical trials
45 drugs studied
Neda Hashemi SadraeiUniversity of New Mexico Cancer Center5 years of reported clinical research
Studies Parotid Gland Cancer
Studies Bladder Cancer
14 reported clinical trials
40 drugs studied
Clinical Trials running at Presbyterian Kaseman Hospital
Breast Cancer
Lung Cancer
Breast cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Parotid Gland Cancer
Uterine Cancer
Multiple Myeloma
Lymphoma
Follicular Lymphoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
CDK4/6 Inhibitors
for Metastatic Breast Cancer
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally daily on days 1-21 of 28-day cycle) vs. TTD using titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) or ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice endocrine therapy (aromatase inhibitor (AI) or fulvestrant) in patients age 65 or older with HR+/HER2- MBC. The secondary and exploratory objectives will generate evidence needed to personalize treatment decisions by comparing patient-centric secondary outcomes and evaluating baseline factors. Together with their treating physician, participants will choose the CDK4/6 inhibitor (palbociclib or ribociclib) and which endocrine therapy (aromatase inhibitor or fulvestrant) of their choice but will be randomized to either Arm 1 (indicated dosing) or Arm 2 (titrated dosing).
Recruiting2 awards Phase 33 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Presbyterian Kaseman Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.